Royal Bank Of Canada Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Hold

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by equities research analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research firms have also recently commented on EYPT. Chardan Capital cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Guggenheim reiterated a “buy” rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Stock Up 12.3%

EYPT opened at $5.47 on Monday. The stock’s 50 day moving average price is $12.97 and its two-hundred day moving average price is $13.55. The firm has a market capitalization of $471.57 million, a P/E ratio of -1.46 and a beta of 1.76. Eyepoint Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. As a group, analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at about $53,658,000. Commodore Capital LP bought a new position in Eyepoint Pharmaceuticals during the first quarter worth about $36,414,000. Paradigm Biocapital Advisors LP bought a new position in Eyepoint Pharmaceuticals during the third quarter worth about $28,556,000. Orbimed Advisors LLC acquired a new stake in Eyepoint Pharmaceuticals during the third quarter valued at approximately $25,575,000. Finally, Suvretta Capital Management LLC boosted its holdings in Eyepoint Pharmaceuticals by 26.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after purchasing an additional 1,634,970 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating while lowering its price target to $17, implying substantial potential upside from current levels. Jefferies also retained a Buy rating, with an $8 target. Benzinga analyst coverage
• Positive Sentiment: Although DURAVYU missed the full-study primary endpoint, EyePoint said the drug was non-inferior to aflibercept in an ad hoc analysis excluding an asymmetric group of patients whose vision loss was unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, durable disease control, supplement-free treatment rates and a favorable redosing safety profile. EyePoint LUGANO trial announcement
• Neutral Sentiment: Unusual options activity was reported, with traders purchasing 3,011 call contracts, about 19% above average call volume. This may reflect speculative expectations for a recovery but does not change the trial outcome.
• Neutral Sentiment: Trading in EYPT was temporarily halted for news before the trial results were released, underscoring the market sensitivity surrounding the announcement.
• Negative Sentiment: The full LUGANO dataset missed the primary endpoint, triggering a roughly two-thirds collapse in the stock and raising questions about DURAVYU’s regulatory path and commercial prospects. The result was widely described as a late-stage trial failure. Reuters trial report
• Negative Sentiment: Analyst sentiment became more cautious: Cantor Fitzgerald downgraded EYPT to Neutral, while Chardan, RBC, JPMorgan and HC Wainwright maintained neutral or sector-perform views. Chardan cut its target to $5 from $65, and RBC and Chardan both set $5 targets, indicating limited near-term upside.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.